{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Daily+dosing&page=16",
    "query": {
      "intervention": "Daily dosing",
      "page": 16
    },
    "page_size": 10
  },
  "pagination": {
    "page": 16,
    "page_size": 10,
    "total_count": 3693,
    "total_pages": 370,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Daily+dosing&page=17&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Daily+dosing&page=15&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-30T17:07:48.801Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05996471",
      "title": "A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "VH3810109",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cabotegravir",
          "type": "DRUG"
        },
        {
          "name": "Standard of care (SOC)",
          "type": "DRUG"
        },
        {
          "name": "rHuPH20",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 185,
      "start_date": "2023-08-17",
      "completion_date": "2028-11-09",
      "has_results": false,
      "last_update_posted_date": "2026-07-29",
      "last_synced_at": "2026-10-30T17:07:48.801Z",
      "location_count": 43,
      "location_summary": "Birmingham, Alabama • Bakersfield, California • Los Angeles, California + 35 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palm Springs",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05996471"
    },
    {
      "nct_id": "NCT02132767",
      "title": "Rate Control Versus Rhythm Control For Postoperative Atrial Fibrillation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Postoperative Atrial Fibrillation"
      ],
      "interventions": [
        {
          "name": "Amiodarone",
          "type": "DRUG"
        },
        {
          "name": "DC-cardioversion",
          "type": "PROCEDURE"
        },
        {
          "name": "Rate Control",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Icahn School of Medicine at Mount Sinai",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 523,
      "start_date": "2014-05",
      "completion_date": "2015-09",
      "has_results": true,
      "last_update_posted_date": "2019-03-15",
      "last_synced_at": "2026-10-30T17:07:48.801Z",
      "location_count": 17,
      "location_summary": "Los Angeles, California • Atlanta, Georgia • Baltimore, Maryland + 13 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02132767"
    },
    {
      "nct_id": "NCT03088930",
      "title": "Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lung Cancer, Nonsmall Cell"
      ],
      "interventions": [
        {
          "name": "Crizotinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 3,
      "start_date": "2017-12-13",
      "completion_date": "2021-01-13",
      "has_results": true,
      "last_update_posted_date": "2022-02-11",
      "last_synced_at": "2026-10-30T17:07:48.801Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03088930"
    },
    {
      "nct_id": "NCT02111564",
      "title": "A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Heart Failure",
        "Respiratory Insufficiency",
        "Stroke Acute",
        "Infectious Diseases",
        "Rheumatic Diseases"
      ],
      "interventions": [
        {
          "name": "Rivaroxaban, 10 mg",
          "type": "DRUG"
        },
        {
          "name": "Rivaroxaban, 7.5 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 12024,
      "start_date": "2014-01-07",
      "completion_date": "2018-05-03",
      "has_results": true,
      "last_update_posted_date": "2019-11-25",
      "last_synced_at": "2026-10-30T17:07:48.801Z",
      "location_count": 135,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Sheffield, Alabama + 132 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Sheffield",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Fort Smith",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02111564"
    },
    {
      "nct_id": "NCT07663422",
      "title": "Mycophenolate Mofetil w/ Prednisone for Immune Related Hepatitis From Checkpoint Inhibitor Therapy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Immune-mediated Hepatitis",
        "Immune-related Adverse Event"
      ],
      "interventions": [
        {
          "name": "Mycophenolate Mofetil plus prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Fox Chase Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 31,
      "start_date": "2026-07-23",
      "completion_date": "2028-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-17",
      "last_synced_at": "2026-10-30T17:07:48.801Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07663422"
    },
    {
      "nct_id": "NCT05096065",
      "title": "Study to Evaluate the Pharmacodynamics and Efficacy of Leuprolide Tablets (Ovarest®) in Women With Endometriosis",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Endometriosis"
      ],
      "interventions": [
        {
          "name": "Leuprolide Oral Tablet - 120 mg - QD- Treatment A",
          "type": "DRUG"
        },
        {
          "name": "Leuprolide Oral Tablet - 80 mg - QD - Treatment B",
          "type": "DRUG"
        },
        {
          "name": "Leuprolide Oral Tablet - 60 mg - QD - Treatment C",
          "type": "DRUG"
        },
        {
          "name": "Leuprolide Oral Tablet - 60 mg - BID - Treatment D",
          "type": "DRUG"
        },
        {
          "name": "Leuprolide Oral Tablet - 40 mg - BID - Treatment E",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Enteris BioPharma Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 49 Years · Female only"
      },
      "enrollment_count": 16,
      "start_date": "2022-03-18",
      "completion_date": "2022-05",
      "has_results": false,
      "last_update_posted_date": "2022-03-22",
      "last_synced_at": "2026-10-30T17:07:48.801Z",
      "location_count": 4,
      "location_summary": "Sarasota, Florida • Columbus, Ohio • Norfolk, Virginia + 1 more",
      "locations": [
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Norfolk",
          "state": "Virginia"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05096065"
    },
    {
      "nct_id": "NCT01670175",
      "title": "Sirolimus With Cyclophosphamide and Topotecan for Pediatric/Adolescent Relapsed and Refractory Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malignant Solid Tumor",
        "Childhood Solid Tumor"
      ],
      "interventions": [
        {
          "name": "Sirolimus, Cyclophosphamide, Topotecan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "Up to 25 Years"
      },
      "enrollment_count": 21,
      "start_date": "2012-08",
      "completion_date": "2016-09",
      "has_results": false,
      "last_update_posted_date": "2017-06-21",
      "last_synced_at": "2026-10-30T17:07:48.801Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01670175"
    },
    {
      "nct_id": "NCT02342353",
      "title": "Pacritinib in Patients With Endothelial Growth Factor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) After EGFR Tyrosine Kinase Inhibitor (TKI)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer",
        "Nonsmall Cell Lung Cancer",
        "Carcinoma, Non-Small-Cell Lung"
      ],
      "interventions": [
        {
          "name": "Pacritinib",
          "type": "DRUG"
        },
        {
          "name": "Erlotinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2015-05-18",
      "completion_date": "2018-02-06",
      "has_results": false,
      "last_update_posted_date": "2018-02-27",
      "last_synced_at": "2026-10-30T17:07:48.801Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02342353"
    },
    {
      "nct_id": "NCT02503137",
      "title": "A Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia Analyzed by Biopsy of the Scalp Prior To and Post Dosing",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Androgenetic Alopecia"
      ],
      "interventions": [
        {
          "name": "Topical SM04554 solution",
          "type": "DRUG"
        },
        {
          "name": "Topical vehicle solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biosplice Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "MALE",
        "summary": "18 Years to 65 Years · Male only"
      },
      "enrollment_count": 49,
      "start_date": "2015-08",
      "completion_date": "2016-04",
      "has_results": true,
      "last_update_posted_date": "2026-10-01",
      "last_synced_at": "2026-10-30T17:07:48.801Z",
      "location_count": 5,
      "location_summary": "Clinton Township, Michigan • Cleveland, Ohio • College Station, Texas + 2 more",
      "locations": [
        {
          "city": "Clinton Township",
          "state": "Michigan"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "College Station",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Lynchburg",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02503137"
    },
    {
      "nct_id": "NCT02848001",
      "title": "A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Leukemia, Myeloid, Acute",
        "Myelodysplastic Syndromes"
      ],
      "interventions": [
        {
          "name": "CC-90009",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 101,
      "start_date": "2016-11-14",
      "completion_date": "2024-04-11",
      "has_results": true,
      "last_update_posted_date": "2025-06-12",
      "last_synced_at": "2026-10-30T17:07:48.801Z",
      "location_count": 6,
      "location_summary": "Stanford, California • New Haven, Connecticut • Chicago, Illinois + 3 more",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02848001"
    }
  ]
}